Generated by AI
Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company that develops medicines for intractable diseases using RNA interference, a gene-silencing approach designed to reduce the production of disease-causing proteins. Arrowhead Pharmaceuticals focuses on therapeutic areas including cardiometabolic, liver, pulmonary, neuromuscular, complement-mediated, and central nervous system disorders. Its portfolio includes both commercial and clinical-stage programs built around its targeted RNAi platform, which is designed for tissue-specific delivery and precise gene suppression. The company works across product development, clinical research, and commercialization, with a pipeline that includes multiple investigational therapies aimed at genetically driven diseases. Arrowhead Pharmaceuticals serves the broader healthcare market by advancing treatments for complex conditions with limited options, positioning itself as a specialized player in RNA-based drug development.
Website177 East Colorado Boulevard
Pasadena, CA, 91105
United States
The latest articles about ARWR.
Summary of Nov 17's posts. Generated by AI.
Summary of Nov 9's posts. Generated by AI.
Summary of Oct 14's posts. Generated by AI.
Summary of Nov 9's posts. Generated by AI.
Investors talking about ARWR also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.